DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Omni Shoreham Hotel

2018年1月21日 (日) 午前 9:00 - 2018年1月21日 (日) 午後 5:00

2500 Calvert Street NW, , Washington, DC 20008 , USA

Course 1: PBRER

Instructors

Melissa  Chan, PharmD

Melissa Chan, PharmD

Aggregate Report Analyst, Safety Evaluation and Reporting , Pfizer, United States

Melissa Chan graduated from The University of Tennessee Health Science Center with a Pharm.D. and pursued a 1-year postgraduate pharmacy residency at Kingsbrook Jewish Medical Center in Brooklyn, New York. She joined Pfizer in 2011 and currently works as an aggregate report analyst in the Safety Evaluation and Reporting department.

Valerie E. Simmons, MD, FFPM

Valerie E. Simmons, MD, FFPM

Senior Medical Fellow, Global Patient Safety, Eli Lilly and Company Ltd, United Kingdom

Dr. Simmons is currently Senior Medical Fellow (formally the EU QPPV) in Global Patient safety for Eli Lilly & Company Ltd. She is a registered physician from the University of London and, since joining the pharmaceutical industry in 1987, she has focused her career drug safety through senior management positions in Glaxo/Glaxo Welcome and Eli Lilly and Co. Val is also an active member of various expert working groups , including the EFPIA Pharmacovigilance Expert Working Group, ICH E2D, E2F, E2C (R2), CIOMS VII and IX and speaks extensively on pharmacovigilance and risk management

Alison  Turney, PharmD

Alison Turney, PharmD

Sr. Director, Global Patient Safety (GPS) Signal Management Process Owner, Eli Lilly and Company, United States

Alison Turney, PharmD Dr. Turney is a Surveillance Business Process Advisor in Global Patient Safety (GPS) at Eli Lilly and Company. She is responsible for coordination of activities and processes within GPS and between GPS and global and local functions within the company to maintain compliance with regulatory requirements worldwide. Alison has over 15 years of experience in Pharmacovigilance and is responsible for the strategy and development of processes to enable appropriate characterization and communication of the benefit risk balance of products for patients including Post-Marketing Safety Surveillance, the Development Safety Update Report (DSUR) and the Periodic Benefit Risk Evaluation Report (PBRER).

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。